SeeTreat is continuously developing and growing.
Keep updated on our latest news.

SeeTreat, a software medical device company with a vision to 'turn on the light' for oncology treatments enabling affordable personalised and precise treatment for every patient, is pleased to announce new Board directors as SeeTreat prepares for commercial release of its first products to clinics. We welcome Dr Richard Hausmann, Associate Professor Tee Lim and Dr Shane La Bianca to our Board from October 2024. They will join existing executive Board members Dr Trang Nguyen (CEO and Co-Founder), Professor Paul Keall (Co-Founder) and Antonia Dalton (Chief Strategy Officer).

Dr Richard Hausmann brings decades of experience in the medtech industry in both publicly listed companies and start-ups in multiple jurisdictions globally. His experience spans GE's Magnetic Resonance division as President and CEO and holding several senior positions at Siemens over more than twenty years. Until recently he was global CEO of Elekta, one of the largest radiation therapy device manufacturer in the world, and has also served as CEO of Combinostics, which uses AI technology to manage the care pathway and improve the lives of patients with neurological disorders. Richard is a member of the board of directors of IBA SA, a global market leader in proton therapy.

Associate Professor Tee Lim is a leading Australian radiation oncologist with a diverse clinical interest in breast, urological cancers, gastrointestinal and lung cancers. He has a broad clinical practice with experience in Canada and the US completing fellowships at both Sunnybrook Toronto and at the University of California, San Francisco Medical Centre. In addition to his oncology work, A/Prof Lim is pioneering in specialised cardiac treatments such as cardiac ablation therapy for cardiac arrythmia and total lymphoid irradiation for cardiac transplantation rejection in Western Australia. As a clinical associate professor at the University of Western Australia, he has made significant contribution to cancer research, co-authoring over 40 published papers and abstracts. He is actively involved in clinical trials, and regularly presents at scientific meetings.

Dr La Bianca is a Urologist with international experience in Australia and Vancouver, Canada. He is an adjunct senior lecturer at the University of Notre Dame. He has over 25 years of clinical uro-oncology experience in the management of bladder and prostate cancer, PSA and hormonal therapy. A self- proclaimed technophile, Dr La Bianca offers a different perspective on SeeTreat technology and the potential applications to improve interventional treatments beyond radiotherapy.

Together these independent Directors will bring new insights to SeeTreat to support us at this critical juncture of taking product from development to clinical practice.

SeeTreat has grown from 2 to 15 full time employees in 18 months and is planning to release two SeeTreat products to market in 2025. The Company has successfully raised over $6m in capital executed two commercial partnerships in Australia and the US. This success is a testament to the market need for our products, our software development team's delivery capability, and our opportunity to truly improve patient outcomes through more precise and personalised radiotherapy treatments. We're looking forward to the next 12 months to focus on getting these products into the hands of the clinical teams and making an impact on patients' lives.

Icon Group (Icon), will be the first to partner with SeeTreat to lead innovation in precision radiation therapy treatment.

SeeTreat is a unique Australian medical software start-up who is solving real clinical problems in radiotherapy through software solutions that are high quality, efficient and patient and user centric.

This collaboration will see Icon trial SeeTreat's software innovation, Dose Review*, at select cancer centres in Australia. Dose Review accurately measures a patient's radiotherapy dose daily to ensure patients receive the right treatment at the right time for their anatomy, which can change during treatment and over time.

In line with Icon's commitment to exceptional patient care and innovation, Icon will be testing and validating Dose Review software at two Queensland locations - Icon Cancer Centre Toowoomba and Icon Cancer Centre Greenslopes. During the trial period, Icon and SeeTreat will work together to make the product suitable for widespread use once commercially released in early 2025.

SeeTreat CEO and Founder, Dr Trang Nguyen said Icon's commitment to improving access to world-class cancer care aligns with SeeTreat's vision and goals.

“Working with Icon has been an absolute pleasure, with both organisations clearly aligned and working toward the same goal of improving patient care. Professor Paul Keall and I founded SeeTreat to “turn the light on for cancer treatment, enabling the treatment team to see what we treat, and know whether the radiation is deposited as planned such that clinicians can course-correct as needed”.

Icon Group Executive Manager of Clinical Care, Trent Aland said this partnership reflects Icon's ongoing commitment to investing in the latest technologies.

“We're excited to be working with a "home grown" Australian innovator who is breaking new ground in radiotherapy innovation and developing software with a focus on improving workflow for clinical teams and most importantly quality of care,” said Trent.

“We're looking forward to trialling this software and hopefully adding it to Icon's leading fleet of radiotherapy technology and improving access to the latest in cancer care across Australia.”

This collaboration is the latest in Icon's investment in strong industry partnerships designed to improve cancer care technology and deliver better patient care and outcomes.

SeeTreat and Icon will work closely throughout the trial and validation period to determine suitability and efficacy of the product before it is released widely.

Dose Review* does not have TGA clearance and not available for sale in any market.

Lumonus and SeeTreat are pleased to announce their partnership to improve personalisation and precision in radiotherapy treatment in the USA in 2025.

Combining Lumonus AI Product with SeeTreat's software solutions means ALL patients can be assured of receiving radiotherapy to the right place at the right time despite changes in tumour size or shape and anatomy over the course of treatment. Our combined software solutions are designed to be user centric, efficient and accessible to all. Our teams are excited to be joining forces to innovate for the benefit of millions of cancer patients each year.

SeeTreat has raised seed funding of $700k! This significant milestone will support development and commercialisation of our products in Australia, the USA and Europe in early 2025. Our first products will improve patient outcomes by personalising and improving precision in radiotherapy treatment. Watch this space!

We are thrilled to announce that SeeTreat will be well represented at ESTRO 2024 in Glasgow. Our CEO, Dr. Trang Nguyen, CPO, Dr. Sean Pollock, Director of Clinical Research, Prof. Paul Keall, and Dr Jeremy Booth will be in attendance from the 3rd to the 7th of May.

This year's theme of Radiation Oncology: Bridging the Care Gap, resounds strongly with SeeTreat's core value of providing equitable treatment to patients around the world.

This event offers a fantastic opportunity for us to showcase the exciting progress SeeTreat has made and explore potential partnerships. If you are attending ESTRO and would like to connect, please reach out to us, and we will facilitate a meeting with our team.

We are pleased to announce the appointment of Antonia Dalton as SeeTreat's Chief Strategy Officer to our company board. Antonia brings a wealth of commercial, financial, and legal expertise, complementing the skills of our existing team.

Her experience will be invaluable as SeeTreat's starts moving forward with partnerships in the Australian, American and European markets. Antonia previously worked as Senior Vice President of Strategy and Innovation at GenesisCare and is bringing that insight into her role as Executive Director at SeeTreat.

(15) Antonia (Abelson) Dalton | LinkedIn

SeeTreat has a successful grant application for the Australian Federal Government Industry Growth Program Advisory Service. The service aims to support innovative enterprises that are creating unique products or significantly enhancing current products.

The program will provide advice in turning future ideas into profitable products and services and includes support surrounding investment, market testing, business models and networking. In addition to the valuable advice on offer, the Industry Growth Program also presents SeeTreat with the ability to apply to grants of up to $5 million for commercialisation and growth projects.

SeeTreat is pleased to announce that, in partnership with the Image X Institute at the University of Sydney, we have successfully received a three-year NHMRC Development Grant to build an exciting new AI medical device.

The Development grant scheme expedites the translation of health and medical research outcomes through to commercialisation within a foreseeable timeframe. The funded research will focus on advancing and investigating a novel AI targeted radiation therapy software device that will personalise radiation therapy targeting to improve patient outcomes for lung, liver, and pancreas cancer patients.

SeeTreat's extensive experience in medical device product development will be invaluable throughout the progress of the grant. SeeTreat founders Professor Paul Keall (also the Director of the Image X Institute) and Dr Trang Nguyen (SeeTreat CEO) are the grant's Chief Investigators A and B respectively.